0000950170-24-075213.txt : 20240618
0000950170-24-075213.hdr.sgml : 20240618
20240618212653
ACCESSION NUMBER: 0000950170-24-075213
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240618
FILED AS OF DATE: 20240618
DATE AS OF CHANGE: 20240618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ji Henry
CENTRAL INDEX KEY: 0001470981
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39852
FILM NUMBER: 241053845
MAIL ADDRESS:
STREET 1: 5370 RUETTE DE MER
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Scilex Holding Co
CENTRAL INDEX KEY: 0001820190
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
BUSINESS PHONE: (650) 516-4310
MAIL ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
FORMER COMPANY:
FORMER CONFORMED NAME: Scilex Holding Company/DE
DATE OF NAME CHANGE: 20221117
FORMER COMPANY:
FORMER CONFORMED NAME: Vickers Vantage Corp. I
DATE OF NAME CHANGE: 20200804
4
1
ownership.xml
4
X0508
4
2024-06-18
0001820190
Scilex Holding Co
SCLX
0001470981
Ji Henry
C/O SCILEX HOLDING COMPANY
960 SAN ANTONIO ROAD
PALO ALTO
CA
94303
true
true
false
false
Executive Chairperson
false
Common Stock
2024-06-18
4
M
false
6000
1.41
A
311273
D
Common Stock
50070
I
By BioVintage, Inc.
Common Stock
2749
I
By BioVintage, Inc.
Common Stock
292264
I
See Footnote
Common Stock
5640
I
By Spouse
Nonstatutory Stock Option (right to buy)
1.41
2024-06-18
4
M
false
6000
0.00
D
2033-10-04
Common Stock
6000
194000
D
1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of Common Stock for each one share of common stock, par value $0.0001 per share, of Sorrento ("Sorrento Common Stock"). The Reporting Person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,749 shares of Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Common Stock.
(Continued from footnote 2) The Put Option settled on March 17, 2023 and resulted in the Reporting Person becoming entitled to receive 2,749 shares of Common Stock at a price of $8.6002 per share of Common Stock, upon the expiration of the lock-up on such shares which is currently set to expire on September 30, 2024.
Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.
/s/ Jaisim Shah, as Attorney-in-Fact
2024-06-18